Prognostic role of microRNAs in breast cancer: A systematic review

Eleni Zografos; Flora Zagouri; Despoina Kalapanida; Roubini Zakopoulou; Anastasios Kyriazoglou; Kleoniki Apostolidou; Maria Gazouli; Meletios-Athanasios Dimopoulos

doi:10.18632/oncotarget.27327

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Prognostic role of microRNAs in breast cancer: A systematic review

Eleni Zografos, Flora Zagouri, Despoina Kalapanida, Roubini Zakopoulou, Anastasios Kyriazoglou, Kleoniki Apostolidou, Maria Gazouli and Meletios-Athanasios Dimopoulos

PDF | Full Text | How to cite

Oncotarget. 2019; 10:7156-7178. https://doi.org/10.18632/oncotarget.27327

Metrics: PDF 1982 views | Full Text 4317 views | ?

Abstract

Eleni Zografos1, Flora Zagouri2, Despoina Kalapanida2, Roubini Zakopoulou2, Anastasios Kyriazoglou2, Kleoniki Apostolidou2, Maria Gazouli1 and Meletios-Athanasios Dimopoulos2

1 Department of Basic Medical Sciences, Laboratory of Biology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

2 Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Correspondence to:

Eleni Zografos,

email:

el_[email protected]

Keywords: breast cancer; microRNAs; prognosis; biomarkers

Received: August 07, 2019 Accepted: October 26, 2019 Published: December 24, 2019

ABSTRACT

MicroRNAs (miRNAs) have been found to play an important role in breast cancer, functioning either as potential oncogenes or tumor suppressor genes, but their role in the prognosis of patients remains unclear. The aim of the present review study is to highlight recent preclinical and clinical studies performed on both circulating and tissue-specific miRNAs and their potential role as prognostic markers in breast cancer. We systematically searched the PubMed database to explore the prognostic value of miRNAs in breast cancer. After performing the literature search and review, 117 eligible studies were identified. We found that 110 aberrantly expressed miRNAs have been associated with prognosis in breast cancer. In conclusion, the collective data presented in this review indicate that miRNAs could serve as novel prognostic tools in breast cancer, while the clinical application of these findings has yet to be verified.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27327

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Prognostic role of microRNAs in breast cancer: A systematic review

Abstract